We report the development of a double-cycle elutriation 
B ability to restore exogenously hematopoietic function, thereby permitting the treatment of childhood malignancies refractory to conventional therapy with potentially curative, marrow-ablative combinations of chemotherapy and irradiation.'-' BMT can also correct congenital or acquired lymphohematopoietic dysfunction.'.'' Patients with leukemia or primary hematopoietic dysfunction benefit optimally from a BMT using an HLA-identical, mixed lymphocyte culture (MLC)-nonreactive sibling donor (a genotypic match).",12 However, genotypic matches are available in only 25% of cases;',12 therefore, alternative BMT strategies have been sought and developed. These include use of related, HLA-disparate allogeneic BMT, unrelated HLAmatched allogeneic BMT (phenotypic match), and autologous BMT, each of which conveys risks beyond those of genotypic allografts. The major limitations to nongenotypic allogeneic BMT are severe graft-versus-host disease (GVHD) and graft reJecti~n.'~"-'~ T-cell depletion of both genotypic and HLA-disparate allografts has been demonstrated to reduce or prevent severe GVHD.'3*'6-2' However, increases in both rejection rate and leukemic relapse due to a loss of the immunologic graft-versus-leukemia (GVL) effect have complicated its use. [18] [19] [20] [22] [23] [24] [25] We have explored elutriation, which separates cells on the basis of size and density,26-28 for T-cell depletion in the setting of HLA-disparate allografts. Elutriation provides adequate T-cell depletion in the setting of genotypic allografts, with investigators reporting a 1.5-to 3-log reduction in T cells. In those studies, patients received between 0.1 and 3.6 X IO6 T c e l l~/ k g .~~-~' We have attempted to overcome both graft rejection and provide a GVL effect by the addition of a defined number of donor T cells to the infused marrow inoculum.
Based on data demonstrating that severe GVHD can be prevented in the HLA-disparate setting by reducing the infused T cells to < 105/kg,32 we modified the elutriation prodisease [VOD] ). Four patient are disease-free survivors (median follow-up, 960 days: range, 670 to 1,035). Group 2 included five infants, four with congenital lymphohematopoietic deficiencies and one with refractory acute lymphocytic leukemia (ALL). In these infants, busulfan and increased cyclophosphamide were substituted for TBI. Only the ALL patient received added T cells. Three patients engrafted: one has stable mixed chimerism, one relapsed with ALL, and one rejected the marrow. One patient had primary autologous recovery, while another failed to engraft. None developed GVHD. We conclude that, in this setting of HLA-disparate BMT with post-BMT antithymocyte globulin (ATG) and corticosteroids, DCE significantly depletes T cells from the marrow and that a defined number of T cells can be added without the occurrence of severe GVHD. cess to reduce consistently T cells by 3 or greater logs. We then performed a pilot study, using extended-cycle elutriation to deplete marrows from HLA-disparate family members of T cells. To these depleted marrows, a defined number of mature T cells, quantitated by flow cytometry, were added to the infused marrow innoculum. In these patients, who also received concomitant in vivo immunosuppression with antithymocyte globulin (ATG) and prednisone, we evaluated whether such a T-cell add-back could be accomplished without incurring severe GVHD. These data provide a basis for future studies of added T-cell subpopulations to promote engraftment and mediate an antileukemic effect.
MATERIALS AND METHODS
Patients and preparative regimens. Patient data are summarized in Table 1 . Fifteen patients received HLA-disparate marrow were transplanted for refractory leukemia. They ranged in age from 14 months to 19 years (mean age. 7.7 years). Four patients (all male) received transplants for congenital lymphohematopoietic disorders (severe combined immunodeficiency disease [SCID], congenital aplastic anemia, Chediak-Higashi) and ranged in age from I month to 16 months (mean age 8.3 months). All marrow donors were biologic parents with the exception of unique patient number (UPN) 9 and 47. whose siblings donated. Patients and their donors were screened for chronic infections including cytomegalovirus (CMV), hepatitis, and human immunodeficiency virus (HIV). Patients were transplanted and cared for in high-efficiency particle air (HEPA)-filtered rooms and were provided sterile beverages and a low-bacteria diet. Patients received prophylactic antibiotics (trimethoprim-sulfamethoxozole and acyclovir), weekly intravenous (IV) IgG, oral IgG (50 mg/kg/d divided four times daily) (except UPN 6), and were started on empiric broad-spectrum antibiotics when febrile. Transfusions of platelets and packed RBCs were administered to maintain platelet counts z 20 X 109/mLand hemoglobin 2 8.5 g/dL, respectively. All blood and blood products were from CMV-seronegative volunteer donors and were irradiated with 2,500 cGy of gamma irradiation ('37Cs. Isomedix, Nordion, Katana, Ontario, Canada). 33 With the exception of the 14-month-old infant (UPN 29), with acute lymphocytic leukemia (ALL) all patients with leukemia received a total body irradiation (TB1)-containing regimen (regimen A). TBI, 1,200 cCy, was delivered using a Clinac 18 linear accelerator (Varian, Palo Alto. CA) at 15 to 20 cGy/min, 200 cGy twice a day for six doses (lung compensation was used to maintain the pulmonary dose equivalent to the central axis dose of 1,200 cGy). IV cytarabine (3,000 mg/m2. twice daily X six doses, except UPN 6 and 8 who received 12 doses). and cyclophosphamide (45 mg/kg/d X two doses) were administered.
The infant with ALL (UPN 29) and the four patientswith congenital hematopoietic disorders received a non-TBI-containing regimen (regimen B) with busulfan ( I mg/kg nasogatrically every 6 hours X 16 doses). cytarabin (100 mg/kg [UPN 31 and 351 or 3.000 mg/m2 IV, twice daily X six doses), and cyclophosphamide (50 mg/kg/d IV X four doses, except UPN 34 who received 30 mg/kg because ofprior CMV cardiomyopathy). In both regimens, 1 day of rest was included between the last dose of cyclophosphamide and the marrow infusion.
Zn/brmed consent. T-cell depletion by elutriation was reviewed and approved by the Institutional Review Board of the Children's National Medical Center. Informed consent for clinical research was obtained from all patients or their families.
Bone murrow hurvest. Donor marrow was harvested in the operating room under anesthesia. Heparinized marrow in Hank's balanced salt solution (without Phenol Red. Ca", or Mg2+t; M.A. Bioproducts, Walkersville, MD) was filtered into blood bags using a closed in-line system (Fenwal. Deerfield. IL). Sequential samples were analyzed for bone marrow-nucleated cell (BM-NC) counts with a Coulter Counter-JT (Hialeah, FL) to obtain 2 1 X IO9 BM-NC/kg recipient weight.
Zmmunopropl?ylru-is. As antirejection therapy, all patients received ATGAM brand (Upjohn, Kalamazoo. MI) ATG ( 1 5 mg/kg/ d IV, days -5 to -3 and every other day from day +5 to + 19) and IV prednisolone (20 mg/kg/d days -5 to -3, I O mg/kg/d days -2 to +2,5 mg/kg d +3 to +8.2 mg/kg d +9 to + 19. 1 mg/kgdays +20 to +30, then a 14-day taper). Because both ATG and prednisolone may provide anti-GVHD prophylaxis. the patients did not receive additional prophylaxis. Acute GVHD was graded from 0 to 4 according to criteria described by Glucksberg et a1.34 Initial marrow processing. Bone marrow in 600-mL blood hags was initially centrifuged at 2,500 rpm for 11.5 minutes at 20°C (Beckman J 6000 centrifuge, Beckman Instruments, Palo Alto, CA) to remove fat. Then the packed RBCs, huffy coats, and 75% of the plasma were collected and recounted. The fat-depleted marrow was further processed to remove RBCs either by automated processing on a Fenwall CS3000 apheresis device using one of two protoc o l~,~~.~~ or manually by double-buffy-coat harvesting. Media for processing on the CS3000 contained 0.9% NaCI, IO U/mL Heparin, and 2.5 pg/mL DNAase (Sigma Chemical, St Louis, MO). BM-NC from either process were subsequently resuspended in elutriation media (E-media) consisting of0.9% NaCI, I mg/mL D-glucose, 1 mg/mL EDTA, pH 7.2 (Whittaker Bioproducts), and 0.1% human serum albumin (HSA; Armour, Kankakee, IL).
Elutriation was performed with a Beckman J-6M Centrifuge-Elutriator set up for single-chamber elutnation, using either the JE-lox (UPN 6 and 8) or the JE-5 (all other patients) rotor and chamber (Beckman Instruments). Chamber and apparatus were sterilized either by autoclaving or chemically, using 10% bleach followed by 70% alcohol, then a I-L 0.9% NaCl rinse.
Using a sterile connecting device (Hemonetics, Braintree, MA), a semiclosed system with two 170-pm in-line filters (Baxter-Travenol, Deerfield, IL) was configured to allow sterile collection of each marrow fraction into Life Cell blood bags (Baxter-Travenol). Counterflow was provided by a peristaltic pump (Masterflex, ColePalmer Instruments, Chicago, IL).
The RBC-depleted BM-NC were resuspended in E-media so that RBCs were 5 7 X 108/mL and BM-NC were I 7 X 107/mL. Two protocols were used to deplete T cells from HLA-disparate marrows, a single-cycle extended elutriation (SCE; Fig IA) and a double-cycle elutriation (DCE), where the first cycle provided a bulk T-cell depletion and the second extended elutriation cycle efficiently depleted T cells (Fig le) . Rotor speeds were kept constant throughout elutriation, at 1,44Og(2,000 rpm for the JE-IOX rotor and 3,000 rpm for the JE-5 rotor). Temperature was maintained at 20°C.
Elutriation. In SCE (Fig IA) , the BM-NC were loaded into the elutriation chamber at 70 mL/min and residual RBCs were eluted to exhaustion (21,200 mL). Media flow rates were then sequentially increased to 1 IO, 130, 140, 150, 160, and I70 mL/min. At each new flow rate, cells ofincrementally larger size were eluted to exhaustion (600 mL). Cells remaining in the chamber were collected by turning the rotor off (RO) and flushing out the chamber with a high flow rate (600 mL). Separated marrow fractions were then sampled for counts and analyses.
In DCE (Fig IB) , the BM-NC were loaded into the elutriation chamber at 1 IO mL/min and residual RBCs were eluted to exhaustion along with most of the lymphocytes (21,200 mL). The media flow rate was then increased to 140 mL/min and cells of intermediate size were eluted to exhaustion (600 mL). Cells remaining in the chamber were collected by turning the rotor off (RO-I fraction) and flushing out the chamber. The RO-I fraction was then loaded into the elutriator at 140 mL/min and an extended elutriation was performed, with cells being eluted to exhaustion (600 mL) at sequentially increased flow rates of 150, 160, and 170 mL/min. Cells remaining in the chamber after the second cycle of elutriation were collected as the RO-2 fraction. Separated marrow fractions were then sampled for counts and subsequent analyses.
To protect cell viability in the RO fraction, cells were pelleted, the E-media was removed, and the RO cells were resuspended in RPMI 1640 (GIBCO, Grand Island, NY) with 2% HSA and 8 pg/mL DNAase. The RO fraction was then placed on a rocking platform at room temperature during the analysis for residual T cells.
Analyses of elutriated marrow fractions included cell count, Coulter volume histogram, both rapid (flow cytometry) and definitive quantification (limiting dilution analysis [LDA]) of T-cell content, and assessment of hematopoietic progenitors. Cell counts and histogram were determined using a Coulter Counter-JT.
T-cell content of elutriation fractions was analyzed by fluorescence versus cell size by forward light scatter using a BD FACS Star Plus with a 488-nm argon laser (Becton-Dickinson, Mountain View, CA). T cells were identified using a combination Analysis. 
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For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From of fluorescinated monoclonal antibodies specific for CD3 and CD5 (Leu-4 fluorescein isothiocyanate [FITC]/Leu-1 FITC, BectonDickinson). Background staining was determined using Thy-1 FITC specific for the murine determinant Thy-I (Becton-Dickinson). Fc receptors were blocked using aggregated human IgG. In most fractions, IO4 cells were evaluated; however, in fractions extensively depleted of T cells (RO fractions, 170, 160) potentially available to be pooled for patient infusion, lo5 cells were analyzed.
LDA was used to quantify residual T cells in the extensively T-cell-depleted marrow fractions. This was based on T-cell growth to polyclonal activation in the presence of excess growth factors, an assay we have previously described." In brief, serially diluted cells were plated in 96-well plates (Costar, Cambridge, MA) and cultured in media supplemented with 10% fetal bovine sera (Hybrimax, Sigma), 5% T-cell growth factor (TCGF; Cellular Products, Buffalo, NY ), recombinant interleukin-2 (50 IU/mL, Cetus, Emeryville, CA), phytohemagglutinin (PHA-M, GIBCO; 16 wg/ mL), and IO5 irradiated (4,000 cGy) allostimulator cells per well (from four to seven cryopreserved, pooled donors). Cultures were incubated at 37°C in 10% C 0 2 for 28 days with weekly 50% supplemented media replacement. Assays were scored for T-cell growth at weeks 3 and 4 by phase microscopy. This LDA has a demonstrated detection on the order of one T-cell per lo6 BM-NC plated.37 Specific controls in each experiment included the pre-elutriation BM-NC fraction to establish the efficiency of the T-cell LDA for that donor, as well as a negative control group with no added experimental cells. T-cell frequencies (f) were calculated using minimum chisquare analysis, assuming a Poisson distribution in plating. Data are expressed either as number of residual T cells per kilogram in eluted fractions, or as the log reduction in T-cell counts per sample calculated as the log reduction of T content = log (fenpenmenfa,/ Committed hetnutopoieric colony assuw Granulocyte-macrophage colony-forming units (CFU-GM) were assayed using a methylcellulose culture Briefly, IO5 cells were cultured in methylcellulose in media supplemented with PHA-conditioned supernatants, erythropoietin, and fetal bovine serum (Terry Fox Laboratories, Vancouver, Canada). Data were calculated as numbers of colonies per I Os cells plated, and expressed as either total CFU-GM or CFU-GM per kilogram. Marrows with less than 150 mL of packed RBCs were processed manually by double centrifugation and buffy-coat harvesting, which did not deplete mature myeloid cells. Yields of RBC-depleted BM-NC were 34.8% for the automated processing (range, 13% to 64%), with CFU-GM recovery of 74% ? 32% (range, 22% t o 100%). Manual processing yields of BM-NC were 7 I % f 19% (range, 49% to loo%), with initial CFU-GM being derived from this fraction (data not shown).
LDA.

fBM-NC).
RESULTS
Initial
Murrow cell sepurution by elutriation. The RBC-depleted BM-NC fractions were resuspended in E-media at 2.9 f 2 X 10' RBCs/mL (range, 0.3 to 6.6), with BM-NC ranging from 2.2 t 2.8 X 107/mL (range, 0.3 to 6.3). The number of elutriation runs was determined by the total number of cellular particles (BM-NC + RBC). As the loading step is a dynamic state with RBCs being eluted throughout, after RBCs have been effectively reduced, the total number of WBCs becomes the crucial variable. Therefore, one elutriation run was performed if the WBC count was less than 1 X 10" and two runs ifthe WBC count was more than I X IO". The BM-NC total was 1.1 f 0.7 X 10" (range, 1.9 to 23), with the residual RBC total being 19.8 i-21.7 X IO"(range, I .4 to 80).
Seven BM-NC were depleted of T cells by SCE in six patients (UPN 6, 8. 9, 10a and b, 13, 20a). The extended elutriation cycle (Fig I A ) was required to provide maximum separation of the stem-cell-enriched, large-cell fraction and residual T cells. SCE provided a yield of 38.7% +-4.6% of the RBC-depleted BM-NC (20.5% +-9.6% of the marrow cells initially harvested; range, 6% to 32%) and 1 16% +-141% CFU-GM (range, 37 to 400). SCE appeared to provide effective T-cell depletion with a 3.2 t 0.4 log reduction in the T-cell content (range, 2.7 to 3.9 logs), as determined by LDA and compared with the pre-elutriation BM-NC ( Table 2 ). The infused marrow fractions (which included the RO fractions) were estimated to contain 6.1 k 3.3 X IO5 T cells/kg (range, 3.2 to 12.3) by flow cytometry assessment; however, most of these T cells (ie, those not added back) had mean fluorescent intensities that were much lower than in the fraction containing significant percentages of T cells (data not shown). Residual T-cell content in the infused marrow fractions as determined by LDA was 1.3 t 0.6 X 1OS/kg (range, 0.7 to > 2). Eleven marrows were depleted of T cells by DCE (Fig 1B) in the remaining 10 patients. DCE (second cycle extended) provided a yield of 34.3% k 9.4% of the RBC-depleted BM-NC (range, 18% to 45%: 19.6% k 1 1% of the marrow cells initially harvested [range, 7.1% to 38.6761) and 84% f 51% CFU-GM (range. 16% to 198%). LDA determinations of residual T cells in the RO-2 fractions were 0.7 2 0.7 X IO5 T cells/kg (range, 0.05 to 2.5), a 3.6 ? 0.5 log reduction (range, 2.5 to 4.2) compared with the pre-elutriation BM-NC (Figs 2 and 3, Table 2 ). By flow cytometry, residual T cells in the infused marrow fractions (which included the RO-2 fractions) were 1.5 f 1.0 X IO5 T cells/kg (range, 0.8 to 4.2), again most with a lower fluorescence intensity compared with T-cell-containing fractions.
Results of the histograms and immunophenotyping by flow cytometry provided the data used to determine which fractions or portions thereof would be infused. The infused marrow grafts all contained the entire RO fraction (except UPN 34 and 35, who each received Y2 of RO), which contained most of the committed hematopoietic stem cells and was depleted of T cells, plus the variable addition of the I70 fraction, 160 fraction, and 150 fraction. Leukemic patients also received a portion of the 140-2 fraction to adjust the content of mature T cells.
Following DCE, the infused T-cell content in the leukemic patients (including UPN 29) was 1.2 f 0.4 X 105/kg based on flow cytometry, while LDA demonstrated infused T cells to be 0.6 f 0.4 X 105/kg. In the nonleukemic pa- Abbreviations: DPLT, depletion; CS, CS 3000; M, manual.
Added T cells/total T cells as determined by flow cytometry (FC). t Total T cells as determined by limiting dilution (LDA). * 50% RO.
tients, the infused T-cell content was 1.9 f 1.5 X 105/kg based on flow cytometry, while LDA showed infused T cells to be 0.3 k 0.4 X 10s/kg.
All marrows were cultured for bacteria and fungi before and after processing. Two ofthe 18 elutriated marrows were contaminated (Corynebacterium and Proprionobacterium) before processing. Fifteen marrows (including the above two) were sterile after processing. Three marrows had positive bacterial cultures following processing (Bacillus, two patients; Coccobacillus, one patient). These were associated with technical difficulties resulting in a break in the closed system during processing. All of these patients were empirically treated with antibiotics. Repeated cultures following infusion ofeluted marrow were negative for the contaminating organisms. None of the preprocessing or postprocessing marrow cultures for fungi was positive, Clinical results. The time to engraftment, complications, rejection, relapse, infections, and outcome of the patients are summarized in Table 3 . Group A patients. All 10 patients who received the TBIcontaining cytoreduction (group A) demonstrated engraftment with a median absolute neutrophil count (ANC) more than 500 by day 22 (range, 19 to 69). In the five assessable patients, the median day of last platelet transfusion (platelets > 2 X 1 0 5 ) was day 54 (range, day 2 1 to 180). No patient in this group rejected the graft. Two patients demonstrated mixed hematopoietic chimerism at day 100 and 270. Two patients have relapsed to date, one child transplanted for juvenile chronic myelogenous leukemia in second blast crisis and an infant with ALL in third complete remission (CR). Five children have developed acute GVHD 2 grade 11. Four patients, receiving 1.9, 2.1, 0.7, and 0.5 X lo5 T cells/kg, respectively, had grade I1 acute GVHD, which was controlled with corticosteroids. The patient who received more than 2 X IO5 T cells/kg determined by LDA experienced grade 111 acute GVHD, which improved with corticosteroids. However, he subsequently died of fulminant adenoviral hepatitis and, at autopsy, demonstrated marked histologic improvement in the cutaneous GVHD. Two children with acute GVHD developed chronic GVHD (skin and liver), and are quiescent after tapering immunosuppressive therapy (with Kamovsky scores of 90% to 100% at days 1,000 and 9 1 5).40 Two patients received marrow boosts due to slow recovery ofthe ANC (UPN 10) and significant infection (UPN 47). Infections were a significant complication for most of these children, with all but UPN 24 having one or more infectious complications, most notably viral infections (Table 3) . Four patients are alive and disease-free at a median follow-up of 960 days (range, 670 to 1,035). Five patients received the busulfancontaining cytoreduction protocol. Three of the five patients demonstrate peripheral blood or bone marrow evidence of engraftment. A patient with SCID engrafted as a stable mixed hematopoietic chimera with lymphoid engraftment. The infant with t(4;ll) ALL in third CR engrafted, but relapsed in host cells at day 32. A multiply
Group B patients.
For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From transfused, 6-month-old infant with a SCID variant with residual T-cell function (<lo%), who presented with combined CMV and pneumocystis pneumonia and CMV cardiomyopathy, initially demonstrated mixed chimerism following BMT. However, complete autologous marrow reconstitution was documented on day 49 and he died of recurrent disseminated CMV on day 95. One classic marrow rejection occurred in a patient transplanted for Chediak-Higashi syndrome in life-threatening accelerated phase. At day 15, he demonstrated a CD3+, CD8' lymphocytosis, followed by complete autologous hematopoietic reconstitution by day 23. His primary disease became quiescent and he was clinically stable for 11 months after BMT, then accelerated. He has recently been retransplanted from the same donor using the regimen A cytoreduction and engrafted. One patient, a multiply transfused child with congenital aplastic anemia (UPN 20), did not demonstrate engraftment, despite two successive attempts at BMT with his mother as the donor. Four of five (except UPN 34) of these children had significant infections ( Table 3) . For patient treatment group A, the 2-year actuarial disease-free survival rate is 40% (Fig 4) . For patient treatment group B, the 1-year actuarial disease-free survival rate is 20%, while the overall survival rate is 40%. Overall, nine of 15 patients died; the causes of death were infection (n = 4; adenovirus, parainfluenza virus, CMV, aspergillus), VOD (n = l), relapse (n = 3), and failure to engraft (n = 1).
DISCUSSION
Allogeneic BMT is potentially curative for pediatric patients with a refractory leukemia or lethal congenital lymphohematopoietic disorders. However, three of four patients do not have an HLA genotypically matched sibling donor. For these patients, an alternate source of marrow is necessary, and each source is associated with specific risks. One alternative source of marrow is autologous marrow, which requires purging and has a high risk of relapse. Furthermore, autologous marrow is not a clinical option for many patients (nine of the 15 in this study) due to either unstable leukemia or primary marrow dysfunction. An alternate allogeneic marrow can be harvested either from a phenotypically HLA-matched unrelated donor located through a marrow registry, or from a HLA-disparate family member. The use of HLA-matched unrelated donors is currently under intensive clinical investigation. However, as the HLA antigens are derived from different origins (different families), there are increases in both incidence and severity of GVHD, as well as in rejection when compared with genotypic HLA-matched BMT.2L,41,42 Other caveats with matched unrelated donors include only 20% of patients finding donors, and underrepresentation of certain HLA types in the registry (UPN 10 and 2 1 had nonproductive searches). A more significant problem is the time to locate a donor for patients with unstable relapsed leukemia (UPN 6,8,9, 13,27,40, and 47) . The use of T-cell depletion to prevent GVHD in HLA-disparate related allogeneic BMT has been successful in the transplantation of infants with SCID.*y9 However, the obstacles to widespread application of T-cell depletion of either genotypically matched or HLA-disparate BMT in the therapy of refractory leukemia have been the increased risks of rejection, leukemic relapse, GVHD, and infection. 18-23, 25 This pilot study was designed to investigate the feasibility of testing our hypothesis that the addition of allogeneic T cells to stem-cell-containing allografts will improve diseasefree survival. The first goal was to design a system that extensively depletes T cells from a marrow stem-cell-enriched fraction to prevent severe GVHD in the setting of HLA-disparate BMT. Elutriation has been used to accomplish this in the setting of genotypic HLA-matched BMT.29-3' In those studies, the depletions reported were 1.5 to 3 logs and patients received T cells in the range of 0.5 to l X 106/kg and required post-BMT anti-GVHD prophylaxis with cyclosporine A with or without methotrexate. We have improved the depletion of T cells, using extended-cycle elutriation, which reproducibly depleted more than 3 logs of T cells, to enable us to perform BMT in the HLA-disparate setting. In our initial SCEs, variability was observed between donors with regard to the elutriation flow rate defining the transition point between lymphocytes and the stem-cell-containing, large-cell fraction. This appeared to vary with the initial T-cell content. We subsequently developed a DCE protocol, in which the first cycle accomplished a bulk T-cell depletion ( 1.5 to 2 logs). The second extended elutriation cycle provided a 23-log depletion, while maintaining more than 80% of hematopoietic progenitor cell activity as determined by CFU-GM (manuscript in preparation). The more than 3 log For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From reduction in T cells was required to allow the control of infused T cells by specific addition to the graft, as compared with the approach of partial or incomplete T-cell depletion reported by The second goal was to define reproducible methods for monitoring T cells during depletion and following T-cell add-back. Our previous experience,44 as well as these studies, demonstrates that flow cytometry provides timely analysis, allowing detection of less than 0.5% residual T cells by the analysis of lo5 cells using fluorescence by 2 pan-T cell monoclonal antibodies versus cell size by forward-light scatter. Therefore, the analysis of T-cell depletion by flow cytometry provides an immediate assurance of a minimum of 2 to 2.5 logs. Further, flow cytometry monitoring of the T-cell content of the T-cell-enriched elutriation fractions allows accurate quantitation of T cells for later addition. However, definitive quantitation of T cells in both the depleted RO fractions and the reconstituted infused marrow innoculum requires the more sensitive LDA.
Our third goal was to achieve hematopoietic reconstitution using HLA-disparate marrow that was T-cell-depleted by extended-cycle elutriation. A cytoreduction protocol was designed to maximize antileukemic, myeloablative therapy and in vivo immunosuppression in a regimen that would be tolerated by patients (protocol A: TBI + cytarabine + cyclophosphamide, ATG and corticosteroids). With this approach, successful engraftment was obtained. Myeloid engraftment (median, day 22; range, day 19 to 69) was comparable to our experience with matched BMT donors and others' results with T-cell-depleted marrows from genotypic, autologous, and HLA-disparate donors. 1820,21,30,31,45, 46 However, platelet engraftment was somewhat delayed (median, day 54; range, day 21 to 180) compared with our matched BMT experience and published results in T-celldepleted marrows from genotypic, autologous, and HLAdisparate donors. '8,29,30,45,46 This may be due, in part, to the use of ATG post-BMT. In this group. there were no graft rejections. The protocol was modified by substituting busulfan and increased cyclophosphamide for TBI (protocol B) to decrease the potential severe neurotoxicity associated with cranial radiation in infants47 and patients without a primary malignancy; however, it was less successful. Notably, 4 of 5 infants who received protocol B had clinical gastrointestinal abnormalities with diarrhea or malabsorption at the time of cytoreductive chemotherapy. Of these 4 infants, 1 rejected with autologous reconstitution, 1 had autologous reconstitution without classical rejection, 1 relapsed with ALL, and I failed to engraft due to either rejection or an undefined congenital stromal deficiency. Our data are insufficient to interpret the efficacy of the busulfan-containing regimen as preparation for T-cell-depleted HLA-disparate allografts. However, frequent gastrointestinal abnormalities in such immunodeficient patients may exacerbate the known vanability of busulfan absorption in the pediatric setting.48249 Therefore, parenteral delivery of cytoreduction chemotherapy may be prudent in such infant recipients of T-cell-depleted HLA-disparate BMT.
In group A recipients of HLA-disparate allografts who had T cells added back to the infused marrow, acute GVHD 2 grade I1 developed in 50% of patients, with only one developing grade 111 AGVHD and none grade IV. Two of seven patients (29%) who were assessable (survival 2 100 days) developed chronic GVHD.
Increased infectious morbidity and mortality remains a recognized and significant problem in recipients of T-celldepleted allogeneic BMT. This is most notable following HLA-disparate BMT,20,21,45 but is also seen following matched BMT20,30 and even T-cell-depleted autologous BMT.46 Infections were frequent in our patients and, although the incidence of fatal infections (40%) is significantly higher than in our matched BMT, it is comparable to reported r e s~l t s .~~,~~,~~
The data presented demonstrate that extended-cycle elutriation of human bone marrow allows the separation of a large-cell fraction (RO fraction), containing pluripotent, For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From self-regenerating hematopoietic progenitors capable of sustained in vivo hematopoiesis as demonstrated by the establishment of long-term full hematopoietic chimeras. Further, these data support the hypothesis that extended-cycle elutriation can provide an effective and reproducible method for separating allogeneic T cells from hematopoietic stem cells in HLA-disparate marrows to abrogate the severe GVHD seen with mismatched BMT. Such elutriation also results in the sterile separation of marrow T cells in an unaltered state, which permits the addition of a defined number of HLA-disparate, donor-marrow-derived T cells (0.5 to 0.75 X lo5 T cells/kg). Finally, the data from protocol A demonstrate that small numbers of mature T cells can be added to the stem-cell-containing marrow fraction without resulting in severe GVHD. Taken together, these data provide the basis for designing trials to test our central hypothesis: that the extensive T-cell depletion provided by the DCE process permits the clinical use and immunobiologic investigation of specifically selected immunocompetent cells in conjunction with stem-cell-enriched allografts to assess their effect on engraftment, GVL, and immunoreconstitution.
